Actively Recruiting
Randomized Crossover Study Evaluating Safety of HFA-152a Versus HFA-134a Propellants Delivered by Metered Dose Inhalers in Adults with Asthma
Led by GlaxoSmithKline · Updated on 2026-09-30
110
Participants Needed
18
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety of two propellant components used in metered dose inhalers MDIs for people with asthma. The study compares a newer propellant called HFA-152a with the commonly used HFA-134a to gather more safety information. This is a Phase 3 randomized study designed to evaluate these propellants when delivered via inhalers. Participants will receive both propellants in two separate treatment periods in a crossover design. Some will use HFA-152a first followed by HFA-134a, while others will receive them in the reverse order. A washout period occurs between the two treatment phases to clear the first propellant before starting the second. During the study, participants will be closely monitored for any adverse events up to 8 weeks. Vital signs such as blood pressure, pulse rate, heart rate, and ECG readings will be measured at specific times. Researchers will assess safety by looking at changes from baseline and any serious side effects. The total participation length covers both treatment periods and follow-up assessments.
CONDITIONS
Brief Title
A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here